Sorry!! The article you are trying to read is not available now.
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Eli Lilly (NY: LLY)
116.79 USD  -0.02 (-0.02%)
Streaming Delayed Price  /  Updated: 7:51 PM EDT, May 24, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 2,054,700
Open 117.53
Bid (Size) 116.28 (1)
Ask (Size) 117.36 (2)
Prev. Close 116.81
Today's Range 116.45 - 117.55
52wk Range 81.65 - 132.13
Shares Outstanding 1,085,430,420
Dividend Yield 1.93%
Performance
YTD
+1.66%
+1.66%
1 Month
-1.22%
-1.22%
3 Month
-5.73%
-5.73%
6 Month
+3.92%
+3.92%
1 Year
+41.10%
+41.10%
Featured News
More News
Most of the profit in the health-care industry is going to drug companies — here’s why you should care
Why pharmaceutical manufacturers’ sky-high profits matter for consumers Read More
category General , Personal Finance , JNJ , and 3 more.
from MarketWatch
Allergan stock slips despite revenue beat, a sign of investors’ worries over company’s future
Allergan posts quarterly results that top estimates, but the company’s stock has struggled as generic competition ramps up. Read More
category IT:NESN , Medical Products , EOLS , and 10 more.
from MarketWatch
Featured News
Read More
Eli Lilly slashes guidance in face of pricing pressures and growing generic competition
category Earnings , SPX , Medical Products , and 7 more.
from MarketWatch
Fed and tech stocks could crack the market rally, warns Wall Street strategist
category Automobiles , Earnings , Manufacturing , and 44 more.
from MarketWatch
Insulin-maker Eli Lilly is scheduled to report earnings Tuesday. Here’s what to expect
category SPX , Earnings , INCY , and 12 more.
from MarketWatch
Beaten-down health-care companies join Apple and Google in earnings parade
category MA , SPX , CI , and 48 more.
from MarketWatch
Lawsuit over migraine deal could be good for Amgen, analysts say
category TEVA , AMGN , General , and 8 more.
from MarketWatch
Wall Street is buzzing about Gilead’s new rheumatoid arthritis drug. Here’s why
category ABBV , SPX , Biotechnology , and 10 more.
from MarketWatch
More News
Read More
Lilly's Lower-Priced Insulin Now Available
from PR Newswire
Consumers Around the Country Turn to Over the Counter Drugs for Relief
from PR Newswire
Lilly's Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions
from PR Newswire
Lilly to Participate in UBS Global Healthcare Conference
from PR Newswire
Data Presentations at ASCO 2019 Highlight Lilly's Targeted Approach to Developing Treatments for Patients Living with Cancer
from PR Newswire
Lilly to Participate in Bank of America Merrill Lynch Health Care Conference
from PR Newswire
What Is Nektar Therapeutics' New Game Plan?
category BMY , Market News , NKTR , and 2 more.
from Motley Fool
Array BioPharma's colorectal cancer combo treatment meets main goals
category companyNews
from Reuters: Company News
Implied JKD Analyst Target Price: $182
category ETFs
from ETF Channel
Here's Why Array BioPharma Is Surging Today
category Market News , ARRY , NVS , and 1 more.
from Motley Fool
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
category Market News , TORC , XBI , and 17 more.
from Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

WHAT'S POPULAR IN THE VILLE